CAR (CARSKNKDC) Peptide Modified ReNcell-Derived Extracellular Vesicles as a Novel Therapeutic Agent for Targeted Pulmonary Hypertension Therapy

  title={CAR (CARSKNKDC) Peptide Modified ReNcell-Derived Extracellular Vesicles as a Novel Therapeutic Agent for Targeted Pulmonary Hypertension Therapy},
  author={J. Wang and Ling-Li Hu and Hui-jie Huang and Y. Yu and Jingshen Wang and Youjia Yu and Kai Li and Y. Li and Tian Tian and Feng Chen},
  pages={1147 - 1160}
Supplemental Digital Content is available in the text. In recent years, mesenchymal stem cells (MSCs)–derived extracellular vesicles (EVs) are emerging as a potential therapeutic agent for pulmonary hypertension (PH). However, the full realization of MSCs-derived EVs therapy has been hampered by the absence of standardization in MSCs culture and the challenges of industrial scale-up. The study was to exploit an alternative replacement for MSCs using currently commercialized stem cell lines for… Expand
Extracellular Vesicles Derived From Human Umbilical Cord Mesenchymal Stem Cells Protect Against DOX-Induced Heart Failure Through the miR-100-5p/NOX4 Pathway
  • Zhenglong Zhong, Yuqing Tian, Xiaoming Luo, Jianjie Zou, Lin Wu, Julong Tian
  • Medicine
  • Frontiers in Bioengineering and Biotechnology
  • 2021
The end result of a variety of cardiovascular diseases is heart failure. Heart failure patients’ morbidity and mortality rates are increasing year after year. Extracellular vesicles (EVs) derivedExpand
Bmi-1 alleviates adventitial fibroblast senescence by eliminating ROS in pulmonary hypertension
  • Kai Li, Yan Li, +9 authors Feng Chen
  • Medicine
  • BMC Pulmonary Medicine
  • 2021
Bmi-1 alleviates the cellular senescence of pulmonary fibroblasts in PH, which expands the pathogenesis of PH and provides a theoretical basis for targeting senescent cells in the treatment of PH. Expand
Hypertension Editors' Picks: Pulmonary Hypertension.
  • Medicine
  • Hypertension
  • 2021
It is concluded that necrosis, through the release of HMGB1 dimers, predisposes males to a progressive form of pulmonary hypertension (PH), and alteration in microbiota composition in pharyngeal swab samples between patients with PH and reference subjects is defined. Expand


Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics.
This review focuses on methods in which EVs can be chemically or biologically modified to broaden, alter, or enhance their therapeutic capability, and examines two broad strategies, which have been used to introduce a wide range of nanoparticles, reporter systems, targeting peptides, pharmaceutics, and functional RNA molecules. Expand
Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency
Exosomes are defined as exosomes that are produced by the “signaling” cells upon specific physiological or environmental cues and harbor cargo capable of modulating the programming of recipient cells, providing some empirical guidance and perspectives on the challenges in bringing exosome-based therapies to clinic. Expand
Investigation of Content, Stoichiometry and Transfer of miRNA from Human Neural Stem Cell Line Derived Exosomes
The miRNA contents of exosomes derived from human neural stem cells (hNSCs) are characterized and next generation sequencing (NGS) technology allowed the identification of a unique set of hNSC derived exosomal miRNAs. Expand
A Novel Cell Penetrating Peptide for the Differentiation of Human Neural Stem Cells
In this work, a novel cell penetrating peptide was developed to deliver RA to human neural stem cells and, subsequently, promote neuronal differentiation. Expand
Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting
This is the first extensive biodistribution investigation of EVs comparing the impact of several different variables, the results of which have implications for the design and feasibility of therapeutic studies using EVs. Expand
Exosome-mediated targeted delivery of miR-210 for angiogenic therapy after cerebral ischemia in mice
In a transient middle cerebral artery occlusion mouse model, the RGD-exo:miR-210 targets the lesion region of the ischemic brain after intravenous administration, resulting in an increase in miR- 210 at the site. Expand
A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy.
Components for successful exosome-based drug delivery, such as choice of donor cell, therapeutic cargo, use of targeting peptide, loading method and administration route are highlighted and discussed with a general focus pertaining to the results obtained in models of different cancer types. Expand
Macrophage Immunomodulation: The Gatekeeper for Mesenchymal Stem Cell Derived-Exosomes in Pulmonary Arterial Hypertension?
The importance of macrophage function in models of PH is highlighted and the development of MSC-based therapies are summarized, focusing on the significance of M SC exosomes (MEx) and the immunomodulatory and homeostatic mechanisms by which such therapies may afford their beneficial effects. Expand
Mesenchymal stromal cell-derived exosomes improve mitochondrial health in pulmonary arterial hypertension.
Direct evidence of an exosome-mediated improvement in mitochondrial function is provided and new insights into the therapeutic potential of exosomes in PAH are contributed. Expand
Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity.
Microcarrier-based 3D culture and TFF allow scalable production of biologically active exosomes from mesenchymal stem cells, and 3D-TFF-exosomes are seven times more potent in small interfering RNA (siRNA) transfer to neurons compared with 2D-UC-Exosomes. Expand